AbbVie Inc. (4AB.DE)
EUR 152.4
(-0.39%)
EUR 152.4
(-0.39%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 26.35 Billion USD | -7.95% |
| 2022 | 31.42 Billion USD | 19.97% |
| 2021 | 28.28 Billion USD | 135.87% |
| 2020 | 21.14 Billion USD | -49.64% |
| 2019 | 16.26 Billion USD | 90.14% |
| 2018 | 13.68 Billion USD | -31.52% |
| 2017 | 11.77 Billion USD | 5.03% |
| 2016 | 10.81 Billion USD | 25.62% |
| 2015 | 9.69 Billion USD | 67.54% |
| 2014 | 6.28 Billion USD | -25.05% |
| 2013 | 6.91 Billion USD | -12.2% |
| 2012 | 6.97 Billion USD | 17.67% |
| 2011 | 4.94 Billion USD | -1.79% |
| 2010 | 6.02 Billion USD | 27.31% |
| 2009 | 5.79 Billion USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 5.94 Billion USD | 28.29% |
| 2024 Q1 | 4.65 Billion USD | -16.12% |
| 2023 Q2 | 5.11 Billion USD | 64.68% |
| 2023 Q4 | 4.18 Billion USD | 71.29% |
| 2023 FY | - USD | -7.95% |
| 2023 Q3 | 2.44 Billion USD | -52.21% |
| 2023 Q1 | 3.1 Billion USD | -48.52% |
| 2022 FY | - USD | 19.97% |
| 2022 Q4 | 6.02 Billion USD | 21.21% |
| 2022 Q3 | 4.97 Billion USD | 144.85% |
| 2022 Q2 | 2.03 Billion USD | -59.64% |
| 2022 Q1 | 5.03 Billion USD | -4.39% |
| 2021 Q2 | 1.88 Billion USD | -58.84% |
| 2021 FY | - USD | 135.87% |
| 2021 Q3 | 4.67 Billion USD | 148.67% |
| 2021 Q4 | 5.26 Billion USD | 12.58% |
| 2021 Q1 | 4.56 Billion USD | 898.6% |
| 2020 FY | - USD | -49.64% |
| 2020 Q3 | 3.18 Billion USD | 28.07% |
| 2020 Q4 | -572 Million USD | -117.96% |
| 2020 Q1 | 3.6 Billion USD | -15.01% |
| 2020 Q2 | 2.48 Billion USD | -31.07% |
| 2019 Q4 | 4.24 Billion USD | 61.04% |
| 2019 Q2 | 3.58 Billion USD | 7.88% |
| 2019 FY | - USD | 90.14% |
| 2019 Q1 | 3.32 Billion USD | 281.25% |
| 2019 Q3 | 2.63 Billion USD | -26.53% |
| 2018 Q1 | 3.04 Billion USD | 11.36% |
| 2018 Q2 | 2.77 Billion USD | -9.15% |
| 2018 FY | - USD | -31.52% |
| 2018 Q3 | 3.27 Billion USD | 18.09% |
| 2018 Q4 | -1.83 Billion USD | -156.1% |
| 2017 Q3 | 2.71 Billion USD | 0.15% |
| 2017 FY | - USD | 5.03% |
| 2017 Q4 | 2.73 Billion USD | 0.88% |
| 2017 Q1 | 2.43 Billion USD | 0.16% |
| 2017 Q2 | 2.71 Billion USD | 11.43% |
| 2016 Q1 | 2.6 Billion USD | 22.93% |
| 2016 FY | - USD | 25.62% |
| 2016 Q3 | 2.51 Billion USD | -0.98% |
| 2016 Q2 | 2.54 Billion USD | -2.23% |
| 2016 Q4 | 2.42 Billion USD | -3.54% |
| 2015 Q3 | 1.89 Billion USD | -0.73% |
| 2015 Q2 | 1.91 Billion USD | -9.17% |
| 2015 Q1 | 2.1 Billion USD | 1436.5% |
| 2015 Q4 | 2.11 Billion USD | 11.43% |
| 2015 FY | - USD | 67.54% |
| 2014 Q1 | 1.35 Billion USD | -17.74% |
| 2014 Q3 | 2 Billion USD | 28.87% |
| 2014 Q4 | 137 Million USD | -93.15% |
| 2014 FY | - USD | -25.05% |
| 2014 Q2 | 1.55 Billion USD | 14.62% |
| 2013 Q1 | 1.32 Billion USD | -32.05% |
| 2013 Q2 | 1.6 Billion USD | 21.74% |
| 2013 Q3 | 1.82 Billion USD | 13.38% |
| 2013 Q4 | 1.64 Billion USD | -9.66% |
| 2013 FY | - USD | -12.2% |
| 2012 Q3 | 1.84 Billion USD | 1.58% |
| 2012 FY | - USD | 17.67% |
| 2012 Q4 | 1.94 Billion USD | 5.19% |
| 2012 Q1 | 1.56 Billion USD | -37.84% |
| 2012 Q2 | 1.81 Billion USD | 15.86% |
| 2011 Q4 | 2.52 Billion USD | 619.51% |
| 2011 Q3 | 350.88 Million USD | -82.54% |
| 2011 Q2 | 2 Billion USD | 53.99% |
| 2011 Q1 | 1.3 Billion USD | 0.0% |
| 2011 FY | - USD | -1.79% |
| 2010 FY | - USD | 27.31% |
| 2009 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bayer Aktiengesellschaft | 4.2 Billion EUR | -526.23% |
| Sanofi | 11.99 Billion EUR | -119.705% |